Abstract
Measures of small and large artery dysfunction have not been investigated in a single cohort for the prediction of cardiovascular (CV) events in patients with nondialysed (ND) chronic kidney disease (CKD). This prospective cohort study aimed to determine whether central pulse wave velocity (cPWV), central pulse pressure (CPP) or microvascular post-occlusive reactive hyperaemia area (PORHHA) independently predict CV events and mortality in CKD-ND. A total of 94 stage 1–5 CKD-ND (65.3±13.1 years; estimated glomerular filtration rate 35.3 (22.8–49.4) ml min−1 per 1.73 m2) patients were followed-up for a median of 52 (36–65) months and had baseline cPWV and CPP measured by applanation tonometry and PORHHA by laser Doppler flowmetry. Multiple failure time Cox regression models were used to determine the predictive role of vascular parameters on CV mortality and events. Based on multiple linear regressions, baseline age, diabetes, CV disease, and systolic blood pressure (SBP) were independently related to cPWV (R2=0.3), SBP and PORHHA to CPP (R2=0.45), whereas CPP was the only parameter independently related to PORHHA (R2=0.16, all P<0.05). During follow-up, 41 CV events occurred (14 CV deaths). In univariate analyses, cPWV (1.07 (1.02–1.13) per m s−1), CPP (1.04 (1.01–1.07) per mm Hg) and lnPORHHA (0.70 (0.58–0.85) per ln(PU × s)) were all related to the outcome. Baseline diabetes (HR 3.07 (1.65–5.68)), lnFGF23 (fibroblast growth factor-23; 1.86 (1.13–3.06) per RU ml−1) and CPP (1.04 (1.01–1.07) per mm Hg) were independent predictors of CV events. The impaired pulsatile component of large arteries (CPP) independently of other vascular markers (cPWV, PORHHA) predicted CV outcomes in CKD-ND. CPP may integrate the information provided by cPWV and PORHHA.
Similar content being viewed by others
References
Schriffin EL, Lipman ML, Mann JF . Chronic kidney disease: effects on the cardiovascular system. Circulation 2007; 116: 85–97.
Foley RN, Parfrey PS, Sarnak MJ . Clinical epidemiology of cardiovascular disease in chronic renal failure. Am J Kidney Dis 1998; 32: S112–S119.
Eknoyan G, Lameire N, Eckardt KU, Kasiske BL, Wheeler DC, Abboud OI et alKidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013 (Suppl 3): S1–S150.
de Jager DJ, Vervloet MG, Dekker FW . Noncardiovascular mortality in CKD: an epidemiological perspective. Nat Rev Nephrol 2014; 10 (4): 208–214.
Safar ME, Blacher J, Pannier B, Guerin AP, Marchais SJ, Guyonvarc'h PM et al. Central pulse pressure and mortality in end-stage renal disease. Hypertension 2002; 39 (3): 735–738.
Blacher J, Guerin AP, Pannier B, Marchais SJ, Safar ME, London GM . Impact of aortic stiffness on survival in end-stage renal disease. Circulation 1999; 99 (18): 2434–2439.
Sakuragi S, Abhayaratna WP . Arterial stiffness: methods of measurement, physiologic determinants and prediction of cardiovascular outcomes. Int J Cardiol 2010; 138 (2): 112–128.
Sengstock D, Sands RL, Gillespie BW, Zhang X, Kiser M, Eisele G . Dominance of traditional cardiovascular risk factors over renal function in predicting arterial stiffness in subjects with chronic kidney disease. Nephrol Dial Transplant 2010; 25 (3): 853–861.
Townsend RR, Chirinos JA, Parsa A, Weir MA, Sozio SM, Lash JP et alChronic Renal Insufficiency Cohort Investigators. Central pulse pressure in chronic kidney disease: a chronic renal insufficiency cohort ancillary study. Hypertension 2010; 56 (3): 518–524.
Ben-Shlomo Y, Spears M, Boustred C, May M, Anderson SG, Benjamin EJ et al. Aortic pulse wave velocity improves cardiovascular event prediction: an individual participant meta-analysis of prospective observational data from 17,635 subjects. J Am Coll Cardiol 2014; 63 (7): 636–646.
Baumann M, Wassertheurer S, Suttmann Y, Burkhardt K, Heemann U . Aortic pulse wave velocity predicts mortality in chronic kidney disease stages 2-4. J Hypertens 2014; 32: 899–903.
Quiroga B, Verdalles Ú, Reque J, García de Vinuesa S, Goicoechea M, Luño J . Cardiovascular events and mortality in chronic kidney disease (stages I-IV). Nefrologia 2013; 33 (4): 539–545.
Kruger A, Stewart J, Sahityani R, O’Riordan E, Thompson C, Adler S et al. Laser Doppler flowmetry detection of endothelial dysfunction in endstage renal disease patients: correlation with cardiovascular risk. Kidney Int 2006; 70: 157–164.
Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G et alThe Task Force for the Management of Arterial Hypertension of the European Society of Hypertension. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J 2007; (12): 1462–1536.
Roman MJ, Devereux RB, Kizer JR, Lee ET, Galloway JM, Ali T et al. Central pressure more strongly relates to vascular disease and outcome than does brachial pressure: the Strong Heart Study. Hypertension 2007; 50: 197–203.
Laurent S, Cockcroft J, Van Bortel L, Boutouyrie P, Giannattasio C, Hayoz D et al. Abridged version of the expert consensus document on arterial stiffness. Artery Res 2007; 1: 2–12.
Salvi P, Lio G, Labat C, Ricci E, Pannier B, Benetos A . Validation of a new non-invasive portable tonometer for determining arterial pressure wave and pulse wave velocity: the PulsePen device. J Hypertens 2004; 22 (12): 2285–2293.
Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T et alEuropean Society of Hypertension Working Group on Vascular Structure and Function; European Network for Noninvasive Investigation of Large Arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens 2012; 30 (3): 445–448.
Farkas K, Nemcsik J, Kolossváry E, Járai Z, Nádory E, Farsang C et al. Impairment of skin microvascular reactivity in hypertension and uraemia. Nephrol Dial Transplant 2005; 20 (9): 1821–1827.
Stiefel P, Moreno-Luna R, Vallejo-Vaz AJ, Beltrán LM, Costa A, Gómez L et al. Which parameter is better to define endothelial dysfunction in a test of postocclusive hyperemia measured by Laser-Doppler flowmetry? Coron Artery Dis 2012; 23: 57–61.
Kubli S, Waeber B, Dalle-Ave A, Feihl F . Reproducibility of laser Doppler imaging of skin blood flow as a tool to assess endothelial function. J Cardiovasc Pharmacol 2000; 36 (5): 640–648.
Prasad N, Sinha A . Clinical queries: malnutrition and co-morbidity in diabetic kidney disease patients. Nephrology 2012; 1: 138–143.
Huang Y, Gou R, Diao Y, Yin Q, Fan W, Liang Y et al. Charlson comorbidity index helps predict the risk of mortality for patients with type 2 diabetic nephropathy. J Zhejiang Univ Sci B 2014; 15 (1): 58–66.
Lieb W, Larson MG, Benjamin EJ, Yin X, Tofler GH, Selhub J et al. Multimarker approach to evaluate correlates of vascular stiffness: the Framingham Heart Study. Circulation 2009; 119 (1): 37–43.
Roman MJ, Devereux RB, Krzer JR, Okin PM, Lee ET, Wang WN et al. High central pulse pressure is independently associated with adverse cardiovascular outcome: the strong heart study. J Am Coll Cardiol 2009; 54: 1730–1734.
van Sloten TT, Schram MT, van den Hurk K, Dekker JM, Nijpels G, Henry RM et al. Local stiffness of the carotid and femoral artery is associated with incident cardiovascular events and all-cause mortality: the Hoorn study. J Am Coll Cardiol 2014; 63 (17): 1739–1747.
Vlachopoulos C, Aznaouridis K, Stefanidis C . Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis. J Am Coll Cardiol 2010; 55 (13): 1318–1327.
Taal MW, Sigrist MK, Fakis A, Fluck RJ, McIntyre CW . Markers of arterial stiffness are risk factors for progression to end stage renal disease among patinets with chronic kidney disease stage 4 and 5. Nephron Clin Prac 2007; 107: c177–c181.
Briet M, Collin C, Karras A, Laurent S, Bozec E, Jacquot C et alNephrotest Study Group. Arterial remodeling associates with CKD progression. J Am Soc Nephrol 2011; 22 (5): 967–974.
Rossi M, Matteucci E, Pesce M, Consani C, Franzoni F, Santoro G et al. Peripheral microvascular dysfunction as an independent predictor of atherosclerotic damage in type 1 diabetes patients: a preliminary study. Clin Hemorheol Microcirc 2013; 54 (4): 381–391.
Feihl F, Liaudet L, Waeber B . The macrocirculation and microcirculation of hypertension. Curr Hypertens Rep 2009; 11 (3): 182–189.
Safar ME, Jankowski P . Central blood pressure and hypertension: role in cardiovascular risk assessment. Clin Sci 2009; 116: 273–282.
Cruickshank K, Riste L, Anderson SG, Wright JS, Dunn G, Gosling RG . Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation 2002; 106 (16): 2085–2090.
Xiao Y, Luo X, Huang W, Zhang J, Peng C . FGF 23 and risk of all-cause mortality and cardiovascular events: A meta-analysis of prospective cohort studies. Int J Cardiol 2014; 174 (3): 824–828.
Turner J, Belch JJF, Khan F . Current concepts in assessment of microvascular endothelial function using laser doppler imaging and iontophoresis. Trends Cardiovasc Med 2008; 18: 109–116.
Acknowledgements
This study was supported by research grants from the Hungarian Kidney Foundation, Hungarian Society of Hypertension and Hungarian Society of Nephrology.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Supplementary Information accompanies this paper on the Journal of Human Hypertension website
Supplementary information
Rights and permissions
About this article
Cite this article
Cseprekál, O., Egresits, J., Tabák, Á. et al. The significance of micro- and macrovascular biomarkers on cardiovascular outcome in chronic kidney disease: a prospective cohort study. J Hum Hypertens 30, 449–455 (2016). https://doi.org/10.1038/jhh.2015.96
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/jhh.2015.96
- Springer Nature Limited